at position EU426 an aspartic acid, a glutamine, an alanine, or a tyrosine;
at position EU433 an aspartic acid;
at position EU436 a threonine;
at position EU438 a glutamic acid, an arginine, a serine, or a lysine; and
at position EU440 a glutamic acid, aspartic acid or a glutamine.
[22] The antigen-binding molecule according to any one of [1] to [21], wherein the modified FcRn binding domain comprises three or more substitutions, wherein the three or more substitutions are one of the combinations set forth in Tables 12 to 13.
[23] The antigen-binding molecule according to any one of [1] to [22], wherein the modified FcRn-binding domain comprises three or more substitutions, wherein the three or more substitutions are one of the combinations set forth in Tables 14 to 15.
[24] The antigen-binding molecule according to any one of [20] to [23], wherein the FcRn-binding domain comprises:
a) at position EU252 a tyrosine, at position EU387 an arginine, at position EU434 a tyrosine, and at position EU436 a valine; or
b) at position EU252 a tyrosine, at position EU422 a glutamic acid, at position EU434 a tyrosine, and at position EU436 a valine; or
c) at position EU252 a tyrosine, at position EU422 an arginine, at position EU434 a tyrosine, and at position EU436 a valine; or
d) at position EU252 a tyrosine, at position EU422 a serine, at position EU434 a tyrosine, and at position EU436 a valine; or
e) at position EU252 a tyrosine, at position EU424 a glutamic acid, at position EU434 a tyrosine, and at position EU436 a valine; or
f) at position EU252 a tyrosine, at position EU424 an arginine, at position EU434 a tyrosine, and at position EU436 a valine; or
g) at position EU252 a tyrosine, at position EU434 a tyrosine , at position EU436 a valine, and at position EU438 a glutamic acid; or
h) at position EU252 a tyrosine, at position EU434 a tyrosine , at position EU436 a valine, and at position EU438 an arginine; or
i) at position EU252 a tyrosine, at position EU434 a tyrosine, at position EU436 a valine, and at position EU438 a serine; or
j) at position EU252 a tyrosine, at position EU434 a tyrosine, at position EU436 a valine, and at position EU440 a glutamic acid.
[25] The antigen-binding molecule according to any one of [1] to [24], wherein the antigen-binding molecule is an antibody.
[26] Use of the antigen-binding molecule according to any one of [1] to [25] in the manufacture of a medicament for improving antigen-binding molecule-mediated antigen uptake into cells.
[27] Use of the antigen-binding molecule according to any one of [1] to [25] in the manufacture of a medicament for

h) at position EU252 a tyrosine, at position EU434 a tyrosine , at position EU436 a valine, and at position EU438 an arginine; or
i) at position EU252 a tyrosine, at position EU434 a tyrosine, at position EU436 a valine, and at position EU438 a serine; or
j) at position EU252 a tyrosine, at position EU434 a tyrosine, at position EU436 a valine, and at position EU440 a glutamic acid.

[Claim 25] The antigen-binding molecule according to any one of claims 1 to 24, wherein the antigen-binding molecule is an antibody.

[Claim 26] Use of the antigen-binding molecule according to any one of claims 1 to 25 in the manufacture of a medicament for improving antigen-binding molecule-mediated antigen uptake into cells.

[Claim 27] Use of the antigen-binding molecule according to any one of claims 1 to 25 in the manufacture of a medicament for reducing the plasma concentration of a specific antigen, wherein the antigen-binding molecule comprises an antigen-binding domain which can bind said antigen.

[Claim 28] A method for improving the pharmacokinetics of an antigen-binding molecule, comprising the step of introducing an amino acid substitution into an FcRn-binding domain of said antigen-binding molecules at one or more of the positions selected from the group consisting of EU238, EU250, EU252, EU254, EU255, EU258, EU286, EU307, EU308, EU309, EU311, EU315, EU428, EU433, EU434, and EU436.

[Claim 29] A method for delaying the elimination of an antigen-binding molecule in a subject, comprising the step of introducing an amino acid substitution into an FcRn-binding domain of said antigen-binding molecule at one or more of the positions selected from the group consisting of EU238, EU250, EU252, EU254, EU255, EU258, EU286, EU307, EU308, EU309, EU311, EU315, EU428, EU433, EU434, and EU436.

[Claim 30] A method of prolonging the plasma retention time of an antigen-binding molecule, comprising the step of introducing an amino acid substitution into an FcRn-binding domain of said antigen-binding molecule at one or more of the positions selected from the group consisting of EU238, EU250, EU252, EU254, EU255, EU258, EU286, EU307, EU308, EU309, EU311, EU315, EU428, EU433, EU434, and EU436.

[Claim 31] A method for increasing the plasma antigen-elimination rate of an antigen-binding molecule, comprising the step of introducing an amino acid substitution into an FcRn-binding domain of said antigen-binding molecule at one or more of the positions selected from the group

(c) selecting an antigen-binding domain of an antigen-binding molecule and altering at least one amino acid in the antigen-binding domain in order to get a pH-dependent antigen-binding domain, or selecting an calcium-ion dependent antigen-binding domain;
(d) obtaining a gene encoding an antigen-binding molecule in which the human FcRn-binding domain and the antigen-binding domain prepared in (a) and (b) are linked and
(e) producing an antigen-binding molecule using the gene prepared in (c),
wherein said antigen-binding molecule produced has an increased binding activity for an FcRn at neutral or acidic pH and a decreased binding activity for an endogenous ADA at neutral pH as compared to the antigen-binding molecule of a)~~a parent antigen-binding domain having an intact FcRn binding domain~~.

[Claim 59] The method according to claim 58, wherein the FcRn binding domain having an increased binding activity for FcRn and pre-existing ADA at neutral or acidic pH ranges and for pre-existing ADA in the neutral pH ranges comprises an amino acid substitution at one or more positions selected from the group consisting of EU238, EU250, EU252, EU254, EU255, EU256, EU258, EU286, EU307, EU308, EU309, EU311, EU315, EU428, EU433, EU434, and EU436.

[Claim 60] The method according to any one of claims 53 to 57, wherein the amino acid substitution introduced in step a) are at three or more positions wherein said three or more positions are one of the combinations set forth in Tables 4 to 7.

[Claim 61] The method according to any one of claims 53 to 60, wherein the amino acid substitutions introduced in step b) are at three or more positions wherein said three or more positions are one of the combinations set forth in Table 10.